Browse RNF20

Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain -
Function

Component of the RNF20/40 E3 ubiquitin-protein ligase complex that mediates monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1). H2BK120ub1 gives a specific tag for epigenetic transcriptional activation and is also prerequisite for histone H3 'Lys-4' and 'Lys-79' methylation (H3K4me and H3K79me, respectively). It thereby plays a central role inb histone code and gene regulation. The RNF20/40 complex forms a H2B ubiquitin ligase complex in cooperation with the E2 enzyme UBE2A or UBE2B; reports about the cooperation with UBE2E1/UBCH are contradictory. Required for transcriptional activation of Hox genes. Recruited to the MDM2 promoter, probably by being recruited by p53/TP53, and thereby acts as a transcriptional coactivator. Mediates the polyubiquitination of isoform 2 of PA2G4 in cancer cells leading to its proteasome-mediated degradation.

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0006378 mRNA polyadenylation
GO:0006397 mRNA processing
GO:0006479 protein methylation
GO:0006513 protein monoubiquitination
GO:0008213 protein alkylation
GO:0010390 histone monoubiquitination
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0016574 histone ubiquitination
GO:0030336 negative regulation of cell migration
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0031062 positive regulation of histone methylation
GO:0031123 RNA 3'-end processing
GO:0031124 mRNA 3'-end processing
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0031440 regulation of mRNA 3'-end processing
GO:0031441 negative regulation of mRNA 3'-end processing
GO:0032259 methylation
GO:0033182 regulation of histone ubiquitination
GO:0033184 positive regulation of histone ubiquitination
GO:0033523 histone H2B ubiquitination
GO:0040013 negative regulation of locomotion
GO:0043414 macromolecule methylation
GO:0043631 RNA polyadenylation
GO:0050684 regulation of mRNA processing
GO:0050686 negative regulation of mRNA processing
GO:0051271 negative regulation of cellular component movement
GO:1900363 regulation of mRNA polyadenylation
GO:1900364 negative regulation of mRNA polyadenylation
GO:1902275 regulation of chromatin organization
GO:1903311 regulation of mRNA metabolic process
GO:1903312 negative regulation of mRNA metabolic process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1905269 positive regulation of chromatin organization
GO:2000146 negative regulation of cell motility
GO:2001166 regulation of histone H2B ubiquitination
GO:2001168 positive regulation of histone H2B ubiquitination
Molecular Function GO:0002039 p53 binding
GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
GO:0003729 mRNA binding
GO:0003730 mRNA 3'-UTR binding
GO:0004842 ubiquitin-protein transferase activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0042393 histone binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0000785 chromatin
GO:0000792 heterochromatin
GO:0031371 ubiquitin conjugating enzyme complex
GO:0033503 HULC complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNF20 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNF20 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.58 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNF20 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0370.853
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1460.933
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1790.898
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2350.281
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4040.828
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0210.993
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2080.552
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1160.946
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3490.85
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.380.775
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9290.631
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0850.105
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNF20 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF20. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF20. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF20.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF20. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNF20 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNF20 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNF20
Namering finger protein 20, E3 ubiquitin protein ligase
Aliases FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNF20 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.